Among patients with osteosarcoma, a low VEGF-A concentration (<12.5 pg/mL) was associated with a better OS (13.2 vs. 8.2 months, p = 0.014) while high soluble MET levels (>300.6 ng/mL) were associated with a better PFS (7.8 vs. 5.4 months, p = 0.016). The gene discussed is MET; the disease is osteosarcoma.